Literature DB >> 2476500

Cell-mediated suppression of HIV-specific cytotoxic T lymphocytes.

P Joly1, J M Guillon, C Mayaud, F Plata, I Theodorou, M Denis, P Debre, B Autran.   

Abstract

CTL specific for HIV have been described in lungs of infected patients at early stages of HIV disease. In order to characterize the evolution over time of HIV-specific CTL, we have analyzed the cytotoxic function and the cell surface phenotype of the alveolar lymphocytes from 41 patients at various stages of HIV disease. We demonstrated a progressive decline of alveolar anti-HIV CTL activity and detected Ts cells from the lungs of patients with advanced HIV disease. These alveolar T cells strongly suppressed the effector phase of anti-HIV CTL lysis. They lacked a marked specificity of function because they also block anti-HLA CTL response and were not restricted by the HLA-class-I transplantation Ag. They displayed the CD3, CD8, and HNK1 markers, were CD4 and CD16 negative, and lacked NK activity. The presence of Ts cells at late stages of HIV disease could thus partly explain the inefficiency of host defenses against HIV.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476500

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

1.  Investigation of alpha nascent polypeptide-associated complex functions in a human CD8(+) T cell ex vivo expansion model using antisense oligonucleotides.

Authors:  N Al-Shanti; C G Steward; R J Garland; A W Rowbottom
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

Review 2.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

3.  Evolution of human immunodeficiency virus type 1 nef and long terminal repeat sequences over 4 years in vivo and in vitro.

Authors:  S Delassus; R Cheynier; S Wain-Hobson
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

Review 4.  AIDS and the lung: update 1995. 4. Role of the human immunodeficiency virus within the lung.

Authors:  J R Clarke; D S Robinson; R J Coker; R F Miller; D M Mitchell
Journal:  Thorax       Date:  1995-05       Impact factor: 9.139

Review 5.  CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease.

Authors:  Marius Strioga; Vita Pasukoniene; Dainius Characiejus
Journal:  Immunology       Date:  2011-06-29       Impact factor: 7.397

6.  Increase of CD57+ T cells in knee joints and adjacent bone marrow of rheumatoid arthritis (RA) patients: implication for an anti-inflammatory role.

Authors:  K Arai; S Yamamura; S Seki; T Hanyu; H E Takahashi; T Abo
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

7.  Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection.

Authors:  M C Aldhous; K C Watret; J Y Mok; A G Bird; K S Froebel
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Trafficking, persistence, and activation state of adoptively transferred allogeneic and autologous Simian Immunodeficiency Virus-specific CD8(+) T cell clones during acute and chronic infection of rhesus macaques.

Authors:  Diane L Bolton; Jacob T Minang; Matthew T Trivett; Kaimei Song; Jennifer J Tuscher; Yuan Li; Michael Piatak; David O'Connor; Jeffrey D Lifson; Mario Roederer; Claes Ohlen
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

9.  A factor from CD8 cells of human immunodeficiency virus-infected patients suppresses HLA self-restricted T helper cell responses.

Authors:  M Clerici; E Roilides; C S Via; P A Pizzo; G M Shearer
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

10.  Subsets of CD8+, CD57+ cells in normal, healthy individuals: correlations with human cytomegalovirus (HCMV) carrier status, phenotypic and functional analyses.

Authors:  E C Wang; J Taylor-Wiedeman; P Perera; J Fisher; L K Borysiewicz
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.